Navigation Links
Further Data on Safety and Efficacy of Cethromycin Presented at 47th Interscience Conference on Antimicrobial Agents and Chemotherapy
Date:9/22/2007

which may enhance efficacy when used as a postexposure prophylaxis for preventing pneumonic tularemia among individuals exposed to aerosolized Francisella tularensis. Thus, cethromycin appears promising as a therapy for tularemia infections.

The FDA has not approved cethromycin as a treatment for CAP or any other indication.

About Advanced Life Sciences

Advanced Life Sciences is a biopharmaceutical company engaged in the discovery, development and commercialization of novel drugs in the therapeutic areas of infection, cancer and inflammation. The Company's lead candidate, cethromycin, is a novel once-a-day antibiotic in late-stage clinical development for the treatment of respiratory tract infections including CAP. For more information, please visit us on the web at http://www.advancedlifesciences.com.

About Cethromycin

Advanced Life Sciences is developing cethromycin, a novel once-a-day antibiotic in response to the emerging bacterial resistance observed in the treatment of community acquired pneumonia (CAP). Cethromycin has been tested in approximately 5,000 human subjects during clinical trials.

The Company has conducted two, pivotal Phase III clinical trials of cethromycin for the treatment of mild-to-moderate CAP. In June of 2007, Advanced Life Sciences released positive results from the first of these two trials, Trial CL-06, which showed that cethromycin met primary and secondary clinical endpoints. Data from the second CAP pivotal trial is expected to be reported in the Fall. The Company believes that cethromycin, if approved, would build upon the growing market opportunity in the antibiotic marketplace and address the critical need for antibiotics that overcome bacterial resistance.

Forward-Looking Statements

Any statements contained in this press release that relate to future plans, events or performance are forward-looking statements within the
'/>"/>

SOURCE Advanced Life Sciences Holdings, Inc.
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5

Related medicine technology :

1. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
2. Molecular Target of Bradmers Neuradiab Further Validated by Independent Findings
3. Phase III Clinical Trial with 4-Month Long-Acting Formulation of Triptorelin: Ipsen Decides Not to Perform Further Administration
4. Further Statistical Analysis of the Recent Phase III trial on Lead Product M6G Shows Additional Benefits
5. New Data on Market-Leading Velcade (Bortezomib) for Injection Further Strengthen Role in Previously Treated Multiple Myeloma
6. Liponex Inc. Reports Further Analysis of CRD5 Phase I/II Clinical Trial Data
7. MIV Therapeutics Announces Pivotal Test Results Further Validating Company Stent Coatings Meet Critical FDA Fatigue Guidelines
8. Managing Preanalytical Processes for Patient Safety
9. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
10. New Phase 3 Study Published in The Lancet Evaluates Efficacy and Safety of Prezista/Ritonavir vs. Kaletra as Part of HIV Combination Therapy in Treatment-Experienced Adults With HIV
11. Cytogen Presents Phase 1 Data Showing Promising Antitumor Activity and Safety Profile of Quadramet at International Myeloma Workshop
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/5/2008)...., Sept. 5 /PRNewswire-USNewswire/ -- A team of,re...at U.S. immigrants from,India and Pakistan take on...heir risks of prostate cancer among male immigrant...r and prostate cancer develop due to many reasons,...jor role in these cancers,",said Jame Abraham, M.D...
(Date:9/4/2008)... in TaqMan(R) real-time PCR testing for the diagno...NTON, Calif., Sept. 4 /- The U.S. Foo...he COBAS(R) TaqMan(R) HBV Test,the first assay fo...he U.S.,The test uses Roche,s real-time PCR techno...NA in a patient,s blood. Doctors may use viral loa...
(Date:9/4/2008)...and, September 4 /- Axentis Pharma AG...s the safety and tolerability,of a new therapeutic...,infection in cystic fibrosis patients. The new fo...to be delivered directly to the site of,infection....ts of two,different doses of the new drug. Initial...
(Date:9/3/2008)...a, Sept. 4 /Xinhua--,Pharma...) today announced,that it has enrolled the first s...ial evaluating Bronchitol in cystic fibrosis suffe... hospitals across North,America, Argentina and Ger...xis seeks approval to market Bronchitol for cystic...
Breaking Medicine Technology:Immigrants From India, Pakistan Face U.S. Prostate, Breast Cancer Risks 2FDA Approves First Hepatitis B Viral Load Test 2FDA Approves First Hepatitis B Viral Load Test 3Cystic Fibrosis Axentis Pharma Initiates Clinical Trial for Lung Infections 2Cystic Fibrosis Axentis Pharma Initiates Clinical Trial for Lung Infections 3Cystic Fibrosis Axentis Pharma Initiates Clinical Trial for Lung Infections 4Second Pivotal Phase 3 Trial In Cystic Fibrosis Begins 2Second Pivotal Phase 3 Trial In Cystic Fibrosis Begins 3Body Image is a Concern for Students of All Ages 23875 1Body Image is a Concern for Students of All Ages 23875 2Transportation Company Angel MedFlight Worldwide Air Ambulance Services Signs Contract with Blue Cross Blue Shield 23871 1Transportation Company Angel MedFlight Worldwide Air Ambulance Services Signs Contract with Blue Cross Blue Shield 23871 2Noesis Health Introduces AdvancedSMAT for Better Management of Cloverleaf Message Files 23867 1Noesis Health Introduces AdvancedSMAT for Better Management of Cloverleaf Message Files 23867 2Dr Richard M Soll Joined WuXi PharmaTech 28NYSE 3A WX 29 as VP of Medicinal Chemistry 23865 1Dr Richard M Soll Joined WuXi PharmaTech 28NYSE 3A WX 29 as VP of Medicinal Chemistry 23865 2
... II GBM study presented at ASCO with cediranib - a... quarter of patients alive,and progression- free a...e/ -- Data for the,investigational agent cediranib...ing of the American Society of Clinical Oncology,(...blastoma (GBM),an invasive form of brain tumor wi...
...itive data on subcutaneous administration show pot...atients -, CHICAGO, June 04, 2007 /PRNewswire-Firs...nnounced the presentation of positive,data for VEL...,multiple myeloma (MM) who have received at least ... a Phase II trial for subcutaneous,(SC) administra...
Other Medicine Technology:Investigational Drug Cediranib (AZD2171) Shows Promise in Patients,With Recurrent Glioblastoma (GBM) 2Investigational Drug Cediranib (AZD2171) Shows Promise in Patients,With Recurrent Glioblastoma (GBM) 3Investigational Drug Cediranib (AZD2171) Shows Promise in Patients,With Recurrent Glioblastoma (GBM) 4New Data on Market-Leading Velcade (Bortezomib) for Injection,Further Strengthen Role in Previously Treated Multiple Myeloma 2New Data on Market-Leading Velcade (Bortezomib) for Injection,Further Strengthen Role in Previously Treated Multiple Myeloma 3New Data on Market-Leading Velcade (Bortezomib) for Injection,Further Strengthen Role in Previously Treated Multiple Myeloma 4New Data on Market-Leading Velcade (Bortezomib) for Injection,Further Strengthen Role in Previously Treated Multiple Myeloma 5New Data on Market-Leading Velcade (Bortezomib) for Injection,Further Strengthen Role in Previously Treated Multiple Myeloma 6New Data on Market-Leading Velcade (Bortezomib) for Injection,Further Strengthen Role in Previously Treated Multiple Myeloma 7
(Date:9/5/2008)...G, Pa., Sept. 5 /PRNewswire-USNewswire/ -- Childre...r access to comprehensive,services to protect thei...n,in grants that were announced today by the Depar...vices for children and families, the department,be...ren,s Services Planning,initiative, ICSP, in 2004....
(Date:9/5/2008)..., Md., Sept. 5 /PRNewswire-USNewswire/ -- The Heal...day announced $39 million in grants to,increase an...centers., "These grants continue President Bush,s...whose services now reach more economically,vulnera...r before," HRSA,Administrator Elizabeth M. Duke sa...
(Date:9/5/2008)...ontrolled, but you need to know what triggers them...thDay News) -- If you are one of the 36 million Am...is nowhere in the United States that is free from ... shows. , Allergies don,t only happen in the sp...ell. In the fall, the most challenging cities to l...
(Date:9/5/2008)...N, Sept. 5 /PRNewswire-USNewswire/ -- Speaker Nanc...upport of the aims of the "Stand,Up to Cancer" tel...re is not a person in our country who has not seen...s 565,000 Americans annually, and each,year there ... must work,together to make eradicating the scourg...
Breaking Medicine News(10 mins):Health News:Pennsylvania Counties Receive Grants to Improve Services for Children 2Health News:HRSA Announces $39 Million in Grants to Expand, Improve Health Center Services 2Health News:No Place Safe From Allergies 2
...responsible for checking the profits and safety of... to the NHS. They have to monitor that only brande...ould be reasonable. The Pharmaceutical Price Regu...nization which monitors and legislates the agreeme...
...ve come up with a disaster-planning guide to help ...nted by tropical storms, hurricanes, tidal waves a...world, people are vulnerable to some sort of natur...ke, flood, hurricane, or tornado. In addition, ter...
...ed over the increasing malfunction of heart device... deaths between 1990 and 2002. The Food and Drug A...ng with physicians and heart-device manufacturers ...llators had failed between 2000 and 2003. Same num...
...he damages in the heart from the use of stem cells...s from mice to repair heart damage in sheep, repor...sue of The Lancet. Heart failure is a major cause ...es, occurring when cells within the heart are dama...
Other Medicine News:Health News:Pharmaceutical industries grant for R&D to be monitored 2Health News:Disaster Planning Guide From Harvard Health Publications 2Health News:Scientists Concerned Over Increasing Malfunction Of Heart Devices 2
The Surgiflex WAVE is a comfortable, easy to use, versatile, and interchangeable suction-irrigation device.
Clinicians are demanding smaller, higher performing systems specifically designed to meet their clinical and operational challenges. The new Philips HD11 XE system provides a powerful architecture fo
The Cardiff Acuity Test is designed specifically for,acuity measurement in children aged 1 to 3 years. The,test is also helpful with other age groups with,intellectual impairment, dementia, hea
InfinixTM CF-i/SP brings revolutionary flexibility to floor-mounted X-ray systems. The unique design enables operators to move the C-arm around the exam table as needed to obtain the optimal angle fo
Medicine Products: